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Abstract
Background:  Airway smooth muscle contributes to the pathogenesis of pulmonary diseases by secreting inflammatory
mediators such as interleukin-8 (IL-8). IL-8 production is in part regulated via activation of Gq-and Gs-coupled receptors. Here
we study the role of the cyclic AMP (cAMP) effectors protein kinase A (PKA) and exchange proteins directly activated by cAMP
(Epac1 and Epac2) in the bradykinin-induced IL-8 release from a human airway smooth muscle cell line and the underlying
molecular mechanisms of this response.
Methods:  IL-8 release was assessed via ELISA under basal condition and after stimulation with bradykinin alone or in
combination with fenoterol, the Epac activators 8-pCPT-2'-O-Me-cAMP and Sp-8-pCPT-2'-O-Me-cAMPS, the PKA activator 6-
Bnz-cAMP and the cGMP analog 8-pCPT-2'-O-Me-cGMP. Where indicated, cells were pre-incubated with the pharmacological
inhibitors Clostridium difficile toxin B-1470 (GTPases), U0126 (extracellular signal-regulated kinases ERK1/2) and Rp-8-CPT-
cAMPS (PKA). The specificity of the cyclic nucleotide analogs was confirmed by measuring phosphorylation of the PKA substrate
vasodilator-stimulated phosphoprotein. GTP-loading of Rap1 and Rap2 was evaluated via pull-down technique. Expression of
Rap1, Rap2, Epac1 and Epac2 was assessed via western blot. Downregulation of Epac protein expression was achieved by siRNA.
Unpaired or paired two-tailed Student's t test was used.
Results: The β2-agonist fenoterol augmented release of IL-8 by bradykinin. The PKA activator 6-Bnz-cAMP and the Epac
activator 8-pCPT-2'-O-Me-cAMP significantly increased bradykinin-induced IL-8 release. The hydrolysis-resistant Epac activator
Sp-8-pCPT-2'-O-Me-cAMPS mimicked the effects of 8-pCPT-2'-O-Me-cAMP, whereas the negative control 8-pCPT-2'-O-Me-
cGMP did not. Fenoterol, forskolin and 6-Bnz-cAMP induced VASP phosphorylation, which was diminished by the PKA inhibitor
Rp-8-CPT-cAMPS. 6-Bnz-cAMP and 8-pCPT-2'-O-Me-cAMP induced GTP-loading of Rap1, but not of Rap2. Treatment of the
cells with toxin B-1470 and U0126 significantly reduced bradykinin-induced IL-8 release alone or in combination with the
activators of PKA and Epac. Interestingly, inhibition of PKA by Rp-8-CPT-cAMPS and silencing of Epac1 and Epac2 expression
by specific siRNAs largely decreased activation of Rap1 and the augmentation of bradykinin-induced IL-8 release by both PKA
and Epac.
Conclusion: Collectively, our data suggest that PKA, Epac1 and Epac2 act in concert to modulate inflammatory properties of
airway smooth muscle via signaling to the Ras-like GTPase Rap1 and to ERK1/2.
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Background
Asthma and chronic obstructive pulmonary disease
(COPD) are chronic inflammatory diseases characterized
by structural and functional changes of the airways [1,2].
The underlying pathogenic processes of asthma and
COPD include the production and release of chemokines
and cytokines by inflammatory and structural cells [3].
Airway smooth muscle cells have recognized as immu-
nomodulatory cells able to synthesize multiple inflamma-
tory mediators such as cytokines, including interleukin-8
(IL-8) [4-6].
IL-8 represents one of the best characterized members of
the family of chemokines known to attract and activate
leukocytes and plays a major role in the initiation and
maintenance of inflammatory responses [7]. In particular,
IL-8 is a potent chemoattractant for neutrophils and eosi-
nophils [8,9], that have been implicated in inflammatory
airway diseases [10]. Indeed, enhanced IL-8 has been
detected in blood and bronchial mucosa [11] and in bron-
chial epithelial cells of patients with asthma [12], in bron-
choalveolar lavage fluid (BALF) of asthmatic and chronic
bronchitis patients [13], in BALF and sputum from
patients with COPD [14,15]. IL-8 levels correlate with the
number of airway neutrophils, which are strongly associ-
ated with severe asthma and are increased during acute
exacerbations of chronic bronchitis [16]. Airway smooth
muscle are a rich source of IL-8 [6]. The gene expression of
IL-8 is tightly regulated by inflammatory and pro-contrac-
tile agonists [6,17,18] acting on the large superfamily of
G-protein-coupled receptors (GPCRs).
Bradykinin is a pluripotent nonapeptide generated by
plasma and tissue kallikreins, and is upregulated in
patients with asthma [19]. It has been reported that brady-
kinin stimulates the expression of IL-8 in human lung
fibroblasts and airway smooth muscle [6,18]. This
response is coupled to activation of extracellular signal-
regulated protein kinases 1 and 2 (ERK1/2) [18,20] and
appears to involve cyclooxygenase-dependent and -inde-
pendent signals [6,21].
Gs-protein-coupled receptor activation (e.g. β2-adrenergic
or prostanoid receptors) modulates the release of
cytokines from airway cells [6], probably via activation of
adenylyl cyclase and subsequent increase in intracellular
cyclic AMP (cAMP). Importantly, a synergism between
bradykinin and the cAMP-elevating agents salmeterol and
prostaglandin E2 (PGE2) has been reported at the level of
IL-6 production from airway smooth muscle [22].
Although these studies clearly indicate a role for cAMP in
pro-inflammatory cytokine production, the engagement
of distinct cAMP-regulated effectors has not been yet
addressed in the airways. Given the importance of the
bradykinin- and the cAMP-driven pathways in both the
pathophysiology and the treatment of pulmonary dis-
eases, insights into the cellular mechanisms of their inter-
action are warranted.
Indeed, increasing evidence suggests that cAMP actively
regulates transcription and gene expression events in sev-
eral airway cells [23,24], and that such mechanism may
regulate local cytokine production in human airway
smooth muscle [21]. Until recently, intracellular effects of
cAMP have been attributed to the activation of protein
kinase A (PKA) and subsequent changes in PKA-mediated
protein expression and function [23]. In the last decade,
exchange proteins directly activated by cAMP (Epac1 and
Epac2) have been identified as cAMP-regulated guanine
nucleotide exchange factors for Ras-like GTPases, such as
Rap1 and Rap2 [25]. Epac controls a variety of cellular
functions including integrin-mediated cell-adhesion [26],
endothelial integrity and permeability [27], exocytosis
and insulin secretion [28,29]. Epac also signals to ERK
although the outcome of this particular signalling appears
to depend on the cell type and specific cellular localiza-
tion of Epac and their effectors [30-33]. Epac has been
shown to act alone [34,35] or to either antagonize [32,36]
or synergize with PKA [37,38]. Although a role of Epac in
lung fibroblasts and airway smooth muscle proliferation
has recently been addressed [34,35,39], the impact of
both PKA and Epac on the production of inflammatory
mediators in the airways is presently unknown. Here, we
report on novel cAMP-driven molecular mechanisms
inducing augmentation of bradykinin-induced release of
IL-8 from human airway smooth muscle and we demon-
strate that Epac1 and Epac2 act in concert with PKA to
modulate this cellular response via signaling to the Ras-
like GTPase Rap1 and ERK1/2.
Methods
Materials
1,4-diamino-2,3-dicyano-1, 4-bis [2-aminophe-
nylthio]butadiene (U0126) and forskolin were purchased
from Tocris (Bristol, UK). 6-Bnz-cAMP, 8-pCPT-2'-O-Me-
cAMP, Rp-8-CPT-cAMPS, Sp-8-pCPT-2'-O-Me-cAMPS and
8-pCPT-2'-O-Me-cGMP were from BIOLOG Life Science
Institute (Bremen, Germany). Fenoterol was from Boe-
hringer Ingelheim (Ingelheim, Germany). Bradykinin,
Na3VO4, aprotinin, leupeptin, pepstatin and mouse anti-
β-actin antibody (A5441), peroxidase-conjugated goat
anti-rabbit (A5420) and peroxidase-conjugated rabbit
anti-mouse (A9044) antibodies were purchased from
Sigma-Aldrich (St. Louis, MO). The anti-phospho-ERK1/2
(P-ERK1/2) (9101), anti-ERK1/2 (9102) and anti-VASP
which also binds to phospho-VASP (P-VASP) (3112) were
from Cell Signaling Technology (Beverly, MA). The anti-
bodies against Rap1 (121, sc-65), Rap2 (124, sc-164) and
caveolin-1 (N-20, sc-894) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA), and the antibodyRespiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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against Rac-1 (Mab 3735) was from Millipore (Billerica,
MA). The mouse monoclonal antibodies against Epac1
and Epac2 were generated and kindly provided by Dr. J. L.
Bos [40]. Clostridium difficile toxin B-1470 was kindly pro-
vided by Drs C. von Eichel-Streiber and H. Genth. DMEM,
FBS, penicillin/streptomycin solution were obtained from
GIBCO-BRL Life Technologies (Paisley, UK). Alamar Blue
solution was from Biosource (Camarillo, CA), the dyazo
die trypan blue from Fluka Chemie (Buchs, Switzerland)
and the Pierce BCA protein assay kit from Thermo Scien-
tific (Rockford, IL). siRNA probes were purchased from
Dharmacon Inc. (Lafayette, CO) and the transfection
vehicle lipofectamine 2000 was from Invitrogen
(Carlsbad, CA). The western lightning ECL solution was
from PerkinElmer Inc. (Waltman, MA) and the IL-8 ELISA
kit from Sanquin (Amsterdam, The Netherlands). All used
chemicals were of analytical grade.
Cell culture, toxin treatment, cell number and viability 
measurements
Human bronchial smooth muscle cell lines, immortalized
by stable ectopic expression of human telomerase reverse
transcriptase enzyme were used for all the experiments
(hTERT-airway smooth muscle cells). The primary human
bronchial smooth muscle cells used to generate these cells
were prepared as described previously [41]. All procedures
were approved by the human Research Ethics Board of the
University of Manitoba. As described previously [42],
each cell line was thoroughly characterized to passage 10
and higher. Passage 10 to 25 myocytes, grown on
uncoated dishes in DMEM supplemented with antibiotics
and 10% FBS, were used. Before each experiments, cells
were serum deprived for one day in DMEM supplemented
with antibiotics. For toxin B-1470 treatment, cells were
treated for 24 hrs with 100 pg/ml toxin B-1470. Toxin-
induced glucosylation of Ras-like GTPases was monitored
by using a specific anti-Rac1 antibody [43], and changes
in cell morphology were monitored by phase-contrast
microscopy, using an Olympus IX50 microscope
equipped with a digital image capture system (Color View
Soft Imaging System). The toxicity of used drugs as well as
their vehicle (DMSO) towards hTERT-airway smooth
muscle cells was determined by an Alamar Blue assay.
Briefly, cells were incubated with HBSS containing 10%
vol/vol Alamar blue solution and then analyzed by fluor-
imetric analysis. Fluorescence derives from the conversion
of Alamar blue into its reduced form by mitochondrial
cytochromes and is therefore a measure of the number of
cells. Viability was set as 100% in control cells. Viability of
cells was also measured by resuspending cells 1:1 in the
diazo dye trypan blue, which is absorbed by non viable
cells, and the number of blue cells was then measured.
Cell fractionation
Cells were lysed in 50 mM Tris (pH 7.4) supplemented
with 1 mM Na3VO4, 1 mM NaF, 10 μg/ml aprotinin, 10
μg/ml leupeptin and 7 μg/ml pepstatin and then frac-
tioned as described earlier [44]. The protein amount of all
the fractions was determined using Pierce protein deter-
mination according to the manifacturer's instructions.
Membrane, cytosolic and nuclear enriched fractions were
subsequently used for detection of Epac1, Epac2, Rap1
and Rap2 expression.
Silencing of Epac1 and Epac2 expression using siRNAs
Cells were transfected with siRNA probes targeted to
either Epac1 or Epac2; the target sequences for human
Epac1 siRNA mixture were: sense: 5'-CGUGGGAACU-
CAUGAGAUG-3' (J-007676-05), sense: 5'-GGACCGA-
GAUGCCCAAUUC-3' (J-007676-06), sense: 5'-
GAGCGUCUCUUUGUUGUCA-3' (J-007676-07), sense:
5'CGUGGUACAUUAUCUGGAA-3' (J-007676-08) and
for the Epac2 siRNA mixture: sense: 5'-GAACACACCU-
CUCAUUGAA-3' (J-009511-05), sense: 5'- GGA-
GAAAUAUCGACAGUAU-3' (J-009511-06), sense: 5'-
GCUCAAACCUAAUGAUGUU-3' (J-009511-07), sense:
5'-CAAGUUAGCACUAGUGAAU-3' (J-009511-08). Non-
silencing siRNA control was used as a control in all siRNA
transfection experiments. Cells were transfected with 200
pmol of appropriate siRNA by using lipofectamine 2000
(1 mg/ml) as vehicle. 6 hrs after transfection, cells were
washed with DMEM supplemented with antibiotics to
reduce toxicity effects of the transfection reagent. Cells
were subsequently analyzed for Epac1 and Epac2 expres-
sion, GTP-loading of Rap1 or IL-8 production.
Activation of Rap1, phosphorylation of ERK1/2-VASP and 
immunoblot analysis
The amount of activated Rap1 and Rap2 was measured
with the pull-down technique by using glutathione S-
transferase (GST)-tagged RalGDS (Ras-binding domain of
the Ral guanine nucleotide dissociation stimulator) as
previously described [45]. For the measurement of the
phosphorylation of ERK1/2 and VASP, cell were lysed fol-
lowed by determination of the protein concentration.
Equal amounts of protein (or samples) were loaded on
10-15% polyacrylamide gels and analyzed for the protein
of interest by using the specific first antibody (dilution
Rap1 and Rap2 1:250, P-ERK 1:1000, ERK 1:500, VASP
1:1000) and the secondary HRP-conjugated antibody
(dilution 1:2000 anti-rabbit or 1:3000 anti-mouse). Pro-
tein bands were subsequently visualized on film using
western lightning plus-ECL and quantified by scanning
densitometry using TotalLab software (Nonlinear
Dynamics, Newcastle, UK). Results were normalized for
protein levels by using specific control proteins.
IL-8 assay
The concentration of IL-8 in the culture medium was
determined by ELISA according to the manifacturer's
instructions (Sanquin, the Netherlands). Results were
normalized for cell number according to Alamar BlueRespiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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measurement. Basal IL-8 levels ranged between 0.3 and
18,8 pg/ml.
Statistical analysis
Data were expressed as the mean ± SEM of n determina-
tions. Statistical analysis was performed using the statisti-
cal software Prism. Data were compared by using an
unpaired or paired two-tailed Student's t test to determine
significant differences. p values < 0.05 were considered to
be statistically significant.
Results
Cyclic AMP-regulated PKA and Epac augment bradykinin-
induced IL-8 release from human airway smooth muscle
Given the importance of IL-8 in airway inflammatory
processes [7], we examined the role of the cAMP-elevating
agent  β2-agonist fenoterol in bradykinin-induced IL-8
release from hTERT-airway smooth muscle cells. As illus-
trated in Fig. 1A, bradykinin induced an increase in the
release of IL-8 from the cells. The concentration of 10 μM
bradykinin appeared to be most effective (~2-fold
increase, P < 0.001) and was chosen for further experi-
ments. The β2-agonist fenoterol at the concentration of 1
μM further enhanced bradykinin-induced IL-8 release of
about 2 fold (P < 0.05), whereas it did not alter basal IL-8
production (Fig. 1B). These data suggest that bradykinin-
induced IL-8 release from hTERT-airway smooth muscle
cells may be augmented by cAMP signaling.
To study whether cAMP-regulated effectors PKA and Epac
participate in this response, we analyzed the role of the
cAMP analogs 6-Bnz-cAMP and 8-pCPT-2'-O-Me-cAMP
known to preferentially activate PKA or Epac, respectively
[46,47]. As shown in Fig. 2, direct activation of PKA by 6-
Bnz-cAMP induced a concentration-dependent augmen-
tation of bradykinin-induced IL-8 release from hTERT-air-
way smooth muscle cells. 500 μM 6-Bnz-cAMP induced
about a 3.5-fold (P  < 0.01) increase on bradykinin-
induced IL-8 release (Fig. 2). As shown for fenoterol, 6-
Bnz-cAMP did not enhance basal cellular IL-8 production
at any concentration measured (Fig. 2). We report here
that hTERT-airway smooth muscle cells express Epac1 and
Epac2 (See later). Therefore, we also used the Epac activa-
tor 8-pCPT-2'-O-Me-cAMP to modulate bradykinin-
induced IL-8 release. As shown in Fig. 3A, treatment of the
cells with 8-pCPT-2'-O-Me-cAMP induced a concentra-
tion-dependent augmentation of this response. 100 μM 8-
pCPT-2'-O-Me-cAMP increased bradykinin-induced IL-8
release by about 2-fold (P < 0.01) (Fig. 3A). Similar to
both the β2-agonist fenoterol and the PKA activator 6-Bnz-
cAMP, the Epac activator 8-pCPT-2'-O-Me-cAMP did not
increase basal IL-8 production at any concentration used
(Fig. 3A). To validate the data obtained with the Epac acti-
vator 8-pCPT-2'-O-Me-cAMP, 8-pCPT-2'-O-Me-cGMP, a
cGMP analogue with substitutions identical to those in 8-
pCPT-2'-O-Me-cAMP which is known to neither activate
protein kinase G nor Epac [34], was used as a negative
control. Moreover, Sp-8-pCPT-2'-O-Me-cAMPS, a phos-
phorothioate derivative of 8-pCPT-2'-O-Me-cAMP that is
resistant to phosphodiesterase hydrolysis [47,48], was
used as an additional Epac activator. Importantly, Sp-8-
pCPT-2'-O-Me-cAMPS (100 μM) mimicked the effects of
the Epac activator 8-pCPT-2'-O-Me-cAMP on bradykinin-
induced IL-8 release from hTERT-airway smooth muscle
cells (P < 0.05), whereas the negative control 8-pCPT-2'-
O-Me-cGMP (100 μM) did not alter this response (Fig.
3B). Again, as shown for the Epac activator 8-pCPT-2'-O-
Me-cAMP, Sp-8-pCPT-2'-O-Me-cAMPS and 8-pCPT-2'-O-
cAMP-elevating agent fenoterol augments bradykinin-induced  release of IL-8 Figure 1
cAMP-elevating agent fenoterol augments bradyki-
nin-induced release of IL-8. hTERT-airway smooth mus-
cle cells were stimulated for 18 hrs with the indicated 
concentrations of bradykinin (A). Cells were incubated for 
30 min without (Basal) or with 1 μM fenoterol. Then, cells 
were stimulated with 10 μM bradykinin for 18 hrs. IL-8 
release was assessed by ELISA as described in Materials and 
Methods. Results are expressed as mean ± SEM of separate 
experiments (n = 3-10). *P < 0.05, ***P < 0.001 compared to 
unstimulated control; #P < 0.05 compared to bradykinin-
stimulated control.Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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Me-cGMP did not alter basal IL-8 release (Fig. 3B). Collec-
tively, these data indicate that augmentation of bradyki-
nin-induced IL-8 release from hTERT-airway smooth
muscle cells is regulated by cAMP, likely through both
PKA and Epac.
To further validate our findings, we analyzed the phos-
phorylation of VASP, known to be phosphorylated at Ser-
157, a PKA-specific site [49], by using a VASP-specific anti-
body that recognizes both phospho-VASP (upper band)
and total VASP (lower band). Phosphorylation of VASP
was not altered by any of the Epac-related cAMP com-
pounds being studied (each 100 μM) (Fig. 4A). In con-
trast, 1 μM fenoterol, 100 μM forskolin and 500 μM 6-
Bnz-cAMP induced VASP phosphorylation (Fig. 4A). In
addition, treatment of the cells with the pharmacological
selective PKA inhibitor Rp-8-CPT-cAMPS blocked phos-
phorylation of VASP by 6-Bnz-cAMP (P  < 0.05) and
largely reduced VASP phosphorylation by forskolin (P =
0.067) and fenoterol (P < 0.05) (Fig. 4B). Bradykinin also
induced VASP phosphorylation (P = 0.055) (Fig. 4B). All
together, these data indicate that the cyclic nucleotides
used in our study specifically activate their primary phar-
macological targets PKA and Epac, and thereby induce
augmentation of bradykinin-induced IL-8 release from
hTERT-airway smooth muscle cells.
Bradykinin-induced IL-8 release is increased by the PKA acti- vator 6-Bnz-cAMP Figure 2
Bradykinin-induced IL-8 release is increased by the 
PKA activator 6-Bnz-cAMP. hTERT-airway smooth mus-
cle cells were stimulated with the indicated concentrations of 
6-Bnz-cAMP in the absence (Basal) or presence of 10 μM 
bradykinin for 18 hrs. IL-8 release was assessed by ELISA. 
Results are expressed as mean ± SEM of separate experi-
ments (n = 3-10). ***P < 0.001 compared to unstimulated 
control; #P < 0.05, ##P < 0.01 compared to bradykinin-stimu-
lated control.
Bradykinin-induced IL-8 release is increased by the Epac acti- vators 8-pCPT-2'-O-Me-cAMP and Sp-8-pCPT-2'-O-Me- cAMPS Figure 3
Bradykinin-induced IL-8 release is increased by the 
Epac activators 8-pCPT-2'-O-Me-cAMP and Sp-8-
pCPT-2'-O-Me-cAMPS. hTERT-airway smooth muscle 
cells were stimulated with the indicated concentrations of 8-
pCPT-2'-O-Me-cAMP (A) or with 100 μM of 8-pCPT-2'-O-
Me-cAMP, Sp-8-pCPT-2'-O-Me-cAMPS and 8-pCPT-2'-O-Me-
cGMP (B) in the absence (Basal) or presence of 10 μM brady-
kinin for 18 hrs. IL-8 release was measured by ELISA. Results 
are expressed as mean ± SEM of separate experiments (n = 
3-9). **P < 0.01, ***P < 0.001 compared to unstimulated con-
trol; #P < 0.05, ##P < 0.01 compared to bradykinin-stimulated 
control.Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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Role of Ras-like GTPases in cAMP-dependent bradykinin-
induced IL-8 release from human airway smooth muscle
PKA and Epac have been reported to modulate GTP-load-
ing of the Ras-like GTPase Rap1 and Rap2 [45,50,51]. In
hTERT-airway smooth muscle cells, Rap1 and Rap2 were
both present at membrane-associated and cytosolic com-
partments (Fig. 5). As shown in Fig. 5A, activation of Epac
by 8-pCPT-2'-O-Me-cAMP induced about a 2-fold increase
in GTP-loading of Rap1 in hTERT-airway smooth muscle
cells (P < 0.01). Activation of PKA by 6-Bnz-cAMP acti-
vated Rap1 by about 1,5-fold (P < 0.05) (Fig. 5A). In con-
trast, activation of Epac or PKA did not induce GTP-
loading of Rap2 (Fig. 5B). To study whether activation of
Ras-like GTPases by cAMP is required for the augmenta-
tion of bradykinin-induced IL-8 release, cells were treated
Effects of cyclic nucleotide analogs and cAMP-elevating  agents on VASP phosphorylation Figure 4
Effects of cyclic nucleotide analogs and cAMP-elevat-
ing agents on VASP phosphorylation. Phosphorylation 
of the PKA effector VASP in the absence (Control) and pres-
ence of 8-pCPT-2'-O-Me-cAMP, Sp-8-pCPT-2'-O-Me-cAMPS, 
8-pCPT-2'-O-Me-cGMP (each 100 μM), 500 μM 6-Bnz-cAMP 
for 15 min was evaluated by using a VASP-specific antibody. 
Equal loading was verified by analysis of β-actin. Representa-
tive blots are shown (A). hTERT-airway smooth muscle cells 
were stimulated for 15 minutes without (Control) or with 
forskolin, 8-pCPT-2'-O-Me-cAMP (each 100 μM), 500 μM 6-
Bnz-cAMP, 1 μM fenoterol and 10 μM bradykinin in the 
absence or presence of 100 μM Rp-8-CPT-cAMPS (B). Rep-
resentative blots are shown above. Equal loading was verified 
by analysis of β-actin. Below are the densitometric quantifica-
tions of n = 3-6 independent experiments. Data are 
expressed as percentage of phospho-VASP over total VASP. 
**P < 0.01, ***P < 0.001 compared to unstimulated control; 
§P < 0.05 compared to basal condition.
Role of Epac and PKA in GTP-loading of Rap1 and Rap2 Figure 5
Role of Epac and PKA in GTP-loading of Rap1 and 
Rap2. hTERT-airway smooth muscle cells were fractioned as 
described in Material and Methods. Expression of membrane-
associated or cytosolic Rap1 (A) and Rap2 (B) was evaluated 
and normalized to the content of the cell fraction-specific 
marker proteins caveolin-1 and β-actin, respectively. hTERT-
airway smooth muscle cells were stimulated for 10 min with-
out (Control) and with 100 μM 8-pCPT-2'-O-Me-cAMP or 
500 μM 6-Bnz-cAMP. Thereafter, GTP-loaded and total Rap1 
(A) or Rap2 (B) were determined as described in Material 
and Methods. Representative immunoblots are shown above 
with the respective densitometric quantifications underneath 
them (n = 3-5). *P < 0.05, **P < 0.01 compared to unstimu-
lated control.Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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with Clostridium difficile toxin B-1470 known to inactivate
Ras family members, including Rap1 [52]. We analyzed
cell morphology and immunoreactivity of the toxin-sub-
strate GTPase Rac1 to monitor the functionality of toxin
B-1470 [43]. Treatment of the cells with 100 pg/ml toxin
B-1470 profoundly altered cell morphology, as demon-
strated by the occurrence of a high number of rounded
cells (Fig. 6A). Toxin B-1470 also completely abolished
Rac1 immunoreactivity under any experimental condi-
tion studied (not shown). Although hTERT-airway
smooth muscle cells were toxin B-1470 sensitive, toxin
treatment lowered cell number only of about 20% (Fig.
6B, upper panel) and did not alter cell viability (not
shown). Importantly, toxin treatment completely reversed
the augmentation of bradykinin-induced IL-8 release by
8-pCPT-2'-O-Me-cAMP and 6-Bnz-cAMP (each P < 0.05),
without affecting IL-8 release by bradykinin alone (Fig.
6B, lower panel). As we show that PKA and Epac induce
GTP-loading of Rap1 and that inhibition of Ras-like
GTPases, including Rap1, largely affect augmentation of
bradykinin-induced IL-8 release by both PKA and Epac,
our data point at Rap1 as an important modulator of this
response.
Role of ERK1/2 in cAMP-dependent bradykinin-induced IL-
8 release from human airway smooth muscle
Although the activation of ERK1/2 by Epac and PKA still
remain controversial [51,53], some reports have shown
that this might occur via Rap1 [32,51,54]. Current evi-
dence also indicates that ERK1/2 regulates the expression
of cytokines induced by several stimuli, including brady-
kinin, via activation of specific transcription factors
[18,22]. To investigate whether ERK1/2 is required for the
Epac- and PKA-mediated augmentation of bradykinin-
induced IL-8 release from hTERT-airway smooth muscle
cells, we first studied the phosphorylation of ERK1/2 in
these cells by 8-pCPT-2'-O-Me-cAMP and 6-Bnz-cAMP. As
shown in Fig. 7A, activation of Epac and PKA induced
marked phosphorylation of both ERK1 and ERK2. In
agreement with earlier studies [18,20], treatment with
bradykinin also induced ERK1/2 phosphorylation and
such stimulatory effect was further enhanced by co-stimu-
lation with 8-pCPT-2'-O-Me-cAMP and 6-Bnz-cAMP (P =
0.06 and P = 0.11, respectively) (Fig. 7B). Importantly, as
shown in Fig. 7C, treatment with toxin B-1470 signifi-
cantly reduced ERK1/2 phosphorylation by 8-pCPT-2'-O-
Me-cAMP (P < 0.05) and 6-Bnz-cAMP (P < 0.01). Thus, it
is reasonable to assume that cAMP-dependent GTPase
activation lies upstream of ERK1/2 activation in hTERT-
airway smooth muscle cells. To investigate the impact of
ERK1/2 on the augmentation of bradykinin-induced IL-8
release by PKA and Epac, cells were treated with U0126, a
selective pharmacological inhibitor of the upstream
kinase of ERK1/2, mitogen-activated protein kinase kinase
(MEK) [55]. As expected, U0126 largely diminished phos-
phorylation of ERK1/2 under any experimental condition
used (P < 0.001) (Fig. 8A). As illustrated in Fig. 8B, aug-
mentation of bradykinin-induced IL-8 release by 6-Bnz-
cAMP and 8-pCPT-2'-O-Me-cAMP was drastically
impaired (P < 0.01 and P < 0.05, respectively) by MEK
inhibition. As expected, treatment with U0126 also
reduced bradykinin-induced IL-8 release (Fig. 8B), con-
firming that ERK1/2 is an important effector regulating IL-
8 production. More important, our data highlight the role
of ERK1/2 in augmenting bradykinin-induced IL-8 release
from hTERT-airway smooth muscle cells by PKA and Epac.
Impact of Ras-like GTPases on bradykinin-induced IL-8  release Figure 6
Impact of Ras-like GTPases on bradykinin-induced 
IL-8 release. hTERT cells were treated for 24 hrs without 
(Control) and with 100 pg/ml of Clostridium difficile toxin B-
1470 (Toxin B-1470). Then, cell morphology was assessed by 
phase-contrast microscopy (A). Cell number was measured 
on the same cells by Alamar blue as described in Material and 
Methods. Data represent percentage of unstimulated control 
(B; upper panel). In addition, IL-8 release was measured on 
supernatant of cells treated with 10 μM bradykinin alone or 
in combination with 100 μM 8-pCPT-2'-O-Me-cAMP or 500 
μM 6-Bnz-cAMP in the absence (Basal) or presence of 100 
pg/ml Toxin B-1470 by using ELISA (B; lower panel). Results 
are expressed as mean ± SEM of separate experiments (n = 
4). *P < 0.05, **P < 0.01 compared to unstimulated control; 
#P < 0.05 compared to bradykinin-stimulated condition; §P < 
0.05 compared to basal condition.Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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Role of Epac and PKA in basal and bradykinin-induced ERK1/2 phosphorylation. Impact of Ras-like GTPases Figure 7
Role of Epac and PKA in basal and bradykinin-induced ERK1/2 phosphorylation. Impact of Ras-like GTPases. 
hTERT-airway smooth muscle cells were stimulated for the indicated period of time (A) or for 5 min without and with 100 μM 
8-pCPT-2-O-Me-cAMP (8-pCPT) or 500 μM 6-Bnz-cAMP in the absence or presence of 10 μM bradykinin (10 min) (B) or 100 
pg/ml Clostridium difficile toxin B-1470 or its vehicle (24 hrs) (C). Phosphorylated ERK1/2 (P-ERK1/2), total ERK1/2 or β-actin 
were detected by specific antibodies. Representative immunoblots are shown with the respective densitometric quantifica-
tions. Data are expressed as fold of ERK1/2 phosphorylation over unstimulated control and represent mean ± SEM of separate 
experiments (n = 5-7). *P < 0.05, **P < 0.01, ***P < 0.001 compared to unstimulated control; §P < 0.05, §§P < 0.01 compared to 
basal condition.Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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PKA and Epac cooperate to activate Rap1 and to augment 
bradykinin-induced IL-8 release from human airway 
smooth muscle
Studies on the molecular mechanisms of cAMP-related
signaling demonstrate that the classical cAMP effector
PKA acts alone or in concert with the novel cAMP sensor
Epac [25,56,57]. To study whether cAMP-regulated PKA
and Epac might cooperate to augment bradykinin-
induced IL-8 release from hTERT-airway smooth muscle
cells, we stimulated the cells with 6-Bnz-cAMP in the pres-
ence of 8-pCPT-2'-O-Me-cAMP and vice versa. The effect of
50 μM 6-Bnz-cAMP on bradykinin-induced IL-8 release
was modulated by 8-pCPT-2'-O-Me-cAMP (Fig. 9A), the
most prominent effect being observed at 30 μM 8-pCPT-
Impact of ERK1/2 on bradykinin-induced IL-8 release and its augmentation by cAMP analogs Figure 8
Impact of ERK1/2 on bradykinin-induced IL-8 release and its augmentation by cAMP analogs. Cells were pre-
treated for 30 min with 3 μM U0126 or vehicle before the addition of 10 μM bradykinin (15 min), 100 μM 8-pCPT-2-O-Me-
cAMP or 500 μM 6-Bnz-cAMP (each 5 min) (A). Phosphorylated ERK1/2 (P-ERK1/2) and total ERK1/2 were detected by spe-
cific antibodies. Representative immunoblots are shown on the left with the respective densitometric quantifications on the 
right (n = 5). Alternatively, cells were treated with bradykinin alone or in combination with 100 μM 8-pCPT-2'-O-Me-cAMP or 
500 μM 6-Bnz-cAMP for 18 hrs. Thereafter, IL-8 release was measured by ELISA (B). Results represent mean ± SEM of sepa-
rate experiments (n = 3-9). *P < 0.05, **P < 0.01, ***P < 0.001 compared to unstimulated control; §P < 0.05, §§P < 0.01, §§§P < 
0.001 compared to basal condition.Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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2'-O-Me-cAMP. In addition, the effects of 10 μM 8-pCPT-
2'-O-Me-cAMP on bradykinin-induced IL-8 release were
enhanced in the presence of 6-Bnz-cAMP and the maxi-
mal response was observed at 100 μM 6-Bnz-cAMP (Fig.
9B). To further validate PKA and Epac cooperative effects,
we used different approaches to specifically inhibit the
two cAMP-driven effectors and we studied the impact of
these inhibitions on GTP-loading of Rap1 and IL-8 release
from hTERT-airway smooth muscle cells.
As shown before, Rp-8-CPT-cAMPS acts as a specific
inhibitor of PKA in hTERT-airway smooth muscle cells.
Interestingly, treatment of cells with Rp-8-CPT-cAMPS
reduced GTP-loading of Rap1 by both 8-pCPT-2'-O-Me-
cAMP and 6-Bnz-cAMP (Fig. 10A). In addition, in the
presence of Rp-8-CPT-cAMPS, augmentation of bradyki-
nin-induced IL-8 release by the PKA activator 6-Bnz-cAMP
and the Epac activator 8-pCPT-2'-O-Me-cAMP was largely
diminished (P  < 0.05), whereas basal and bradykinin-
induced IL-8 release were not significantly altered (Fig.
10B). These data suggest that PKA and Epac pathways
Cooperativity of 8-pCPT-2'-O-Me-cAMP and 6-Bnz-cAMP on  bradykinin-induced IL-8 release Figure 9
Cooperativity of 8-pCPT-2'-O-Me-cAMP and 6-Bnz-
cAMP on bradykinin-induced IL-8 release. hTERT-air-
way smooth muscle cells were incubated with 50 μM 6-Bnz-
cAMP alone or in combination with the indicated concentra-
tions of 8-pCPT-2'-O-Me-cAMP (A). Alternatively, cells were 
stimulated with 10 μM 8-pCPT-2'-O-Me-cAMP alone or in 
combination with the indicated concentrations of 6-Bnz-
cAMP (B). After that, 10 μM bradykinin was added for 18 hrs 
and IL-8 levels were measured by ELISA. Results represent 
mean ± SEM of separate experiments (n = 3). *P < 0.05, **P < 
0.01 compared to unstimulated control.
Impact of PKA inhibition on Rap1 activation and bradykinin- induced IL-8 release Figure 10
Impact of PKA inhibition on Rap1 activation and 
bradykinin-induced IL-8 release. Cells were treated for 
30 min without (Basal) or with 100 μM Rp-8-CPT-cAMPS. In 
A, cells were first incubated with 100 μM 8-pCPT-2'-O-Me-
cAMP or 500 μM 6-Bnz-cAMP for 5 min followed by meas-
urement of GTP-loading of Rap1 as described in Material and 
Methods. Shown is a representative immunoblot. Alterna-
tively, cells were stimulated with 10 μM bradykinin alone or 
in combination with 100 μM 8-pCPT-2'-O-Me-cAMP or 500 
μM 6-Bnz-cAMP for 18 hrs (B). IL-8 release was then 
assessed by ELISA. Results are expressed as mean ± SEM of 
separate experiments (n = 3-7). *P < 0.05, **P < 0.01, com-
pared to unstimulated control, §P < 0.05 compared to basal 
condition.Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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work in concert both at the level of Rap1 activation and
the downstream production of IL-8.
At present, highly specific pharmacological inhibitors of
individual Epac isoforms, Epac1 and Epac2, are not avail-
able [46]. Thus, to more precisely study the role of Epac1
and Epac2 in specific functions, siRNA is generally used to
suppress their endogenous expression [31,34-36]. As
illustrated in Fig. 11A, the siRNA approaches were effec-
tive in reducing expression of membrane-associated
Epac1 and cytosolic Epac2 of about ~40% (P < 0.01 for
Epac1 and for Epac2) leaving the expression of the cell
fraction-specific marker proteins caveolin-1 and β-actin
unaffected. Silencing of Epac1 and Epac2 was most effi-
cient 72 hrs after transfection, indicating that the proteins
exhibit a slow turn-over rate in hTERT-airway smooth
muscle cells. As illustrated in Fig. 11B, silencing of Epac1
and Epac2 did not only reduced GTP-loading of Rap1 by
8-pCPT-2'-O-Me-cAMP, but also its activation by 6-Bnz-
cAMP. In addition, silencing of Epac1 and Epac2 severely
impaired augmentation of bradykinin-induced IL-8
release by 8-pCPT-2'-O-Me-cAMP (each P  < 0.05),
whereas basal and bradykinin-induced IL-8 release were
again not significantly changed (Fig. 11C). Intriguingly,
silencing of Epac1 also significantly reduced augmenta-
tion of bradykinin-induced IL-8 release by 6-Bnz-cAMP (P
< 0.05) (Fig. 11C). Silencing of cellular Epac2 appeared to
modestly reduce the PKA-mediated IL-8 response,
although this effect was not significant (P = 0.075) (Fig.
11C). Taken together, these data indicate that cAMP-regu-
lated PKA and Epac (Epac1 and Epac2) are interconnected
with regard to the activation of Rap1 and the cellular pro-
duction of IL-8 in hTERT-airway smooth muscle cells.
Discussion
Bradykinin is known to enhance the expression of several
cytokines in airway smooth muscle [18,58]. cAMP-elevat-
ing agents also modulate release of cytokines from airway
sources including airway smooth muscle [59]. For exam-
ple, prostaglandin E2 (PGE2) was shown to increase IL-8
production in airway smooth muscle cells [6]. Interest-
ingly, salmeterol and PGE2 have been reported to aug-
ment bradykinin-induced production of IL-6 by airway
smooth muscle [22], but the cAMP-regulated targets
responsible for this cellular response have not been iden-
tified. Here we report on novel cAMP-dependent mecha-
nisms that augment bradykinin-induced release of IL-8
from airway smooth muscle. We demonstrate that aug-
mentation of bradykinin-induced IL-8 production by
cAMP signaling requires the cooperative action of PKA
and Epac, leading subsequently to the activation of Ras-
like GTPases such as Rap1 and ERK1/2 (Fig. 12).
The use of cyclic nucleotide analogs as pharmacological
tools to study the specific effects of cAMP-driven signaling
is now widely accepted [46]. However, studies indicated
that various cyclic nucleotide analogs, including 6-Bnz-
cAMP and 8-pCPT-2'-O-Me-cAMP might, in addition to
their primary effects, also cause elevation of cAMP or
cGMP upon inhibition of phosphodiesterases [47] or act
upon production of cAMP hydrolysis products [48]. We
did not observe indirect activation of the PKA-dependent
effectors such as VASP by any of the Epac-related analogs.
Moreover, phosphorylation of VASP by forskolin, fenote-
rol and 6-Bnz-cAMP was sensitive to the PKA inhibitor
Rp-8-CPT-cAMPS. Both the PKA activator 6-Bnz-cAMP
and the Epac activators used (8-pCPT-2'-O-Me-cAMP and
Sp-8-pCPT-2'-O-Me-cAMPS) augmented bradykinin-
induced IL-8 release in the cells, whereas no alteration of
the cellular IL-8 levels was observed with the cGMP analog
8-pCPT-2'-O-Me-cGMP. Hence, it is reasonable to assume
that PKA- and Epac-related cyclic nucleotides act via their
primary pharmacological targets. Collectively, our results
indicate that cAMP-dependent augmentation of bradyki-
nin-induced IL-8 release from hTERT-airway smooth mus-
cle cells is regulated by both PKA and Epac.
In agreement with studies in human airway smooth mus-
cle [22], the β2-agonist fenoterol and the distinct PKA/
Epac-related cyclic nucleotide analogs used in our studies
solely alter the release of IL-8 from hTERT-airway smooth
muscle in the presence of bradykinin, suggesting that this
GPCR ligand might also directly affect the cAMP pathway.
Previous studies have shown that bradykinin can increase
intracellular levels of cAMP in airway smooth muscle via
induction of cyclooxygenase and subsequent production
of PGE2 [60]. As we observed phosphorylation of VASP by
bradykinin already ≤ 15 minutes, such prostanoid-driven
indirect effects may not account for the bradykinin
responses observed in our study. Protein kinase C, a major
downstream effector of bradykinin, has been reported to
activate type II adenylyl cyclase (AC) in intact cells and to
elicit activation of basal AC activity [61]. The type II AC
isoform is abundantly expressed in airway smooth muscle
and is activated by both Gαs and PKC probably leading to
synergistic cAMP formation [62,63]. Moreover, PKC may
cooperate in assembling the prostanoid synthetic machin-
ery [60]. In addition, it has been reported that bradykinin
inhibits approximately 60% of the total cAMP phos-
phodiesterase activity in guinea-pig airway smooth mus-
cle [20]. The above mentioned mechanisms could
therefore contribute to the increase of cAMP levels by
bradykinin in distinct subcellular compartments and sub-
sequently trigger the activation of PKA and Epac in airway
smooth muscle.
Here we also focused on the Ras-like GTPase family mem-
bers Rap1 and Rap2 as the main effectors of Epac being
identified [25,64] and so far the best described in their
functional association to Epac [25]. Indeed, both Rap1Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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Impact of Epac silencing on Rap1 activation and bradykinin-induced IL-8 release Figure 11
Impact of Epac silencing on Rap1 activation and bradykinin-induced IL-8 release. hTERT-airway smooth muscle 
cells were transfected for 72 hrs with control siRNA, Epac1 or Epac2 specific siRNAs (each 200 pmol). Thereafter, expression 
of membrane-associated Epac1 or cytosolic Epac2 was evaluated and normalized to the content of the cell fraction-specific 
marker proteins caveolin-1 and β-actin, respectively. Representative immunoblots are shown on the left with the respective 
densitometric quantifications on the right. Results are expressed as mean ± SEM of separate experiments (n = 5-7). Trans-
fected cells were treated with 100 μM 8-pCPT-2'-O-Me-cAMP (8-pCPT) or 500 μM 6-Bnz-cAMP for 5 min and the amount of 
GTP-Rap1 was determined as described in Material and Methods. Shown is a representative immunoblot. In C, transfected 
cells were incubated with 10 μM bradykinin alone or in combination with 100 μM 8-pCPT-2'-O-Me-cAMP (8-pCPT) or 500 μM 
6-Bnz-cAMP for 18 hrs. IL-8 release was then assessed by ELISA. Results are expressed as mean ± SEM of separate experi-
ments (n = 3-7). **P < 0.01, ***P < 0.001 compared to unstimulated control; §P < 0.05, §§P < 0.01 compared to control siRNA.Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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and Rap2 are present in hTERT-airway smooth muscle
cells in both membrane and cytosolic compartments.
Interestingly, activation of PKA and Epac induced GTP-
loading of Rap1 in hTERT-airway smooth muscle; both
cAMP effectors did not alter basal Rap2 activity. In con-
trast to Epac1, activation of Rap1 by PKA has been
reported to occur mostly indirectly. Evidence suggests that
PKA might either activate the Rap1 exchange factor C3G
(Crk Src homology domain 3) and Src [51,54,65] or
inhibit the Rap1-GTPase activating protein [66]. How-
ever, it is presently unknown whether such mechanisms
are operational in hTERT-airway smooth muscle. To
address the role of Ras-like GTPases in bradykinin-
induced IL-8 release we used the bacterial toxin B-1470.
Toxin B-1470, which is produced by C. difficile strain
1470, inhibits exclusively the Rac protein from the Rho
family and, in addition, Rap and Ral proteins from the Ras
family of GTPases via glucosylation [52]. Such GTPases
are important regulators of cellular adhesion and migra-
tion. Indeed, treatment with the toxin induced morpho-
logical changes and also caused cell detachment probably
associated with inhibition of those GTPases. Toxin treat-
ment only slightly reduced cell number and did not alter
cell viability. Importantly, we observed a drastic reduction
of bradykinin-induced IL-8 release by PKA and Epac after
incubation with Toxin B-1470. Hence, our results suggest
that cAMP-dependent augmentation of bradykinin-
induced IL-8 requires PKA- and Epac-dependent activa-
tion of GTPases, and based on the results presented
herein, Rap1 represents a very attractive candidate.
The production and release of IL-8 from airway smooth
muscle upon stimulation of pro-inflammatory agonists is
regulated by gene transcription and protein expression
events [21]. Bradykinin has been shown to modulate the
release of IL-8 generally upon activation of distinct signals
including ERK1/2 [18,20]. Phosphorylation of ERK1/2 by
bradykinin occurs acutely between 5-30 min in both
human airway smooth muscle cells [22] and human lung
fibroblasts [18]. It is generally believed that cAMP modu-
lates transcription and protein expression [23,67], and its
effects have been attributed to the phosphorylation of
cAMP response element binding (CREB) protein by PKA
and its subsequent binding to the CRE promoter of the
specific genes [67]. Although the human IL-8 promoter
does contain a CRE region, activation of CREB has not
been related to the regulation of IL-8 expression in airway
cells. Moreover, recent studies indicate that Epac1 also
modulates gene transcription and protein expression by
inducing the transcription factors CCAAT/Enhancer-bind-
ing Proteins (C/EBPs) in COS-1 cells [68]. Interestingly,
both PKA and Epac have been reported to activate ERK1/
2 in a cell-type specific manner [51]. Once activated,
ERK1/2 signals to the nucleus, promoting transcription of
genes usually associated with inflammation and prolifer-
ation. Activation of Epac and PKA in hTERT-airway
smooth muscle cells increased basal ERK1/2 phosphoryla-
tion (1-30 min) and enhanced bradykinin-induced ERK1/
2 phosphorylation measured after 10 min. Hence, these
findings indicate that ERK1/2 activation may be an impor-
tant mechanism by which β2-agonists augment IL-8 pro-
duction in airway smooth muscle. This was confirmed by
the fact that treatment with the pharmacologic inhibitor
U0126 reduced the IL-8 release by bradykinin alone and
even in a more pronounced way, by the combination of
bradykinin with both 8-pCPT-2'-O-Me-cAMP and 6-Bnz-
cAMP. The fact that toxin B-1470 treatment largely
impaired ERK1/2 phosphorylation by PKA and Epac,
most likely places ERK1/2 downstream of toxin B-1470-
sensitive GTPases.
Previous studies in human lung fibroblasts have shown
that Epac1, Epac2 and PKA act independently on distinct
cellular functions [34,35]. For example, the anti-prolifera-
tive signalling properties in human lung fibroblasts have
been assigned to Epac1, but not to Epac2 [34,35]. The
diverse effects of Epac proteins and PKA could be
explained by their different subcellular localization [69]
or downstream effector availability [70,71]. Indeed, we
observed that Epac isoforms Epac1 and Epac2 exhibit dif-
ferent cellular localization in hTERT-airway smooth mus-
cle cells, the former being more expressed at the plasma
membrane and the latter in the cytosolic fraction of the
cells. However, we here demonstrate that silencing of
Epac1 or Epac2 expression in hTERT-airway smooth mus-
cle cells abolished the augmentation of bradykinin-
induced IL-8 release by the Epac activator 8-pCPT-2'-O-
Me-cAMP, and also largely diminished the enhancement
of this cellular response by the PKA activator 6-Bnz-cAMP.
These data point at a positive cooperativity between
cAMP-regulated Epac1-Epac2 and PKA, which was con-
firmed by pharmacological approaches using the PKA
inhibitor Rp-8-CPT-cAMPS and the combinations of the
the PKA and Epac activators. Importantly, activation of
Rap1 by either PKA or Epac appeared to be sensitive to
inhibition of PKA by Rp-8-CPT-cAMPS or to silencing of
Epac1 and Epac2 by siRNA. This results suggest that Epac
and PKA work in concert to activate Rap1 and subse-
quently augment IL-8 release by bradykinin. Our findings
might implicate that both Epac isoforms and PKA bind to
the same signalling complex which are then directed to
the same target(s). Indeed, distinct intracellular cAMP sig-
naling compartments have been recently identified in pri-
mary cultures of neonatal cardiac ventriculocytes [72] and
cAMP-responsive multiprotein complexes including PKA
and Epac1-Epac2 seem to confer signaling specificity
[73,74]. Thus, our data indicate that in airway smooth
muscle both Epac1 and Epac2 act in concert with PKA to
modulate pro-inflammatory signaling properties.Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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Augmentation of bradykinin-induced IL-8 release in hTERT-airway smooth muscle cells by Epac and PKA Figure 12
Augmentation of bradykinin-induced IL-8 release in hTERT-airway smooth muscle cells by Epac and PKA. Acti-
vation of ERK1/2 is mediated via different GPCRs. The β2-agonist fenoterol acts on Gs-coupled receptors inducing cAMP eleva-
tion via activation of adenylyl cyclase (AC) while forskolin directly activates AC. cAMP activates two distinct cellular effectors: 
PKA and Epac, followed by activation of Ras-like GTPases, such as Rap1, and ERK1/2, and subsequently induction of specific 
transcription factors resulting in the production of IL-8. Bradykinin also elicits ERK1/2 phosphorylation most likely via activa-
tion of Gq-coupled receptors. The dotted line represents a potential pathway which has not been fully addressed in our study. 
⊥ indicates inactivation and → indicates activation, see text for further details.Respiratory Research 2009, 10:88 http://respiratory-research.com/content/10/1/88
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Conclusion
We describe novel cAMP-dependent mechanisms to
induce augmentation of bradykinin-induced IL-8 release
from airway smooth muscle. Evidence is provided that
cAMP-regulated Epac1 and Epac2 cooperate with PKA to
induce Ras-like GTPases activation (presumably Rap1)
and subsequent activation of ERK1/2. Our findings impli-
cate that PKA, Epac1 and Epac2 exert pro-inflammatory
signaling properties in human airway smooth muscle
depending on the input of distinct GPCR signals. The rel-
evance of these findings is reflected by the importance of
bradykinin- and cAMP-mediated signals in airway disease
pathogenesis and treatment and opens new avenues for
future therapeutic intervention.
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